Get Report in 5 to 7 Working Days
Global Gene Editing Market: Snapshot
Gene editing or genome editing is the targeted insertion or modification of cells in living organism or cells and the method has come to occupy a crucial part of biomedical researches, constantly transforming various disciplines of life sciences. Over the past few years, continuous advancements in gene-editing technologies have led to the advent of several versatile methods, which have enabled investigators to introduce a number of sequence-specific changes into the genomes of a variety of cell types. This has facilitated the discovery of promising human gene therapies proving useful for treating various diseases. The use of targeted nucleases or engineered nucleases in laboratories has provided researchers potential tools to economically and rapidly manipulate almost any genomic sequence for a broad range of cell types.
In recent years, gene editing techniques have been witnessed a paradigmatic shift with the advent of methods such as clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs). Using these technologies, investigators have been successful in generating a wide spectrum of outcomes, which are likely to prove useful in diverse areas as synthetic biology, disease modeling, neurosciences, and drug discovery. For instance, targeted nuclease have enabled the insertion of targeted DNA double-strand breaks (DSBs). This has led to the activation of DNA repair pathways in various cells. In vivo applications of various gene editing tools, however, suffer from noticeable constraints. For instance, nuclease delivery or expression can be enabled only in diseased cells, thereby limiting potential of the market to an extent. Nevertheless, constant engineering advances are being made which will expectedly lay robust groundwork for expanding the current array of genome-modifying tools.
Global Gene Editing Market: Overview
Gene editing involves the insertion, deletion, or replacement of DNA at specific sites in the genome of a cell or an organism. It is usually achieved in a laboratory environment using molecular scissors.
Regulations for the security of life, well-being of plants and animals, human health, and environmental compliance will influence market players for increased focus on import, export, and commercialization of genetically modified organisms (GMOs).
The report is an all-important tool to comprehend the various factors and growth trends that will influence the growth of the gene editing market between 2017 and 2025. The market study is a collective of facts and factoids that are associated with the global gene editing market in a chronological order. The analysis of past data and current market trends enable research analysts to present a satisfactory conclusion regarding the market’s future. Thus, the analysis presented in the report can be used to devise successful business strategies for the future. Using standard analytical tools such as Porter’s Five Forces and SWOT analysis, the report presents the indices of strength, weakness, opportunities, and threats of the global gene editing market until the end of the forecast period in 2025.
Global Gene Editing Market: Drivers and Restraints
The increasing expenditures on research and development, growth of the biotechnology and pharmaceutical companies, and rising demand for synthetic genes are the major factors driving the global gene editing market.
The increasing prevalence of infectious diseases, cancer, and other genetic disorders is steering the growth of the gene editing industry. Moreover, the increasing demand for personalized medicine and advancement of medical science is propelling the industry’s demand.
However, strict government regulations to receive approval for mutation undertakings and lack of public awareness will challenge the growth of the gene editing market. Government regulations for assessing the medical benefits as well as the potential hazards of gene editing procedure will benefit the growth of this market.
Global Gene Editing Market: Market Segmentation
The global gene editing market can be analyzed on the basis of technology, end user, application, and region. In terms of technology, the market can be segmented into CRISPR, ZFN, TALEN and others. On the basis of application, the global gene editing market can be divided into cell line engineering, plant genetic engineering, animal genetic engineering, and others. By end user, the market can be segmented into biotechnology and pharmaceutical companies, contract research organizations, and academic and government institutes.
Global Gene Editing Market: Regional Outlook
The global gene editing market can be divided into the regional segments of North America, Europe, Asia Pacific, and Rest of the World. The U.S. gene editing market is expected to display robust growth due to growth trend manifested by biotechnology and pharmaceutical companies and adoption of advanced technologies such as CRISPR for treating chronic hereditary diseases.
In Europe, the U.K. is expected to contribute significantly to the growth of the gene editing market in this region. This is mainly due to the rising geriatric population and increasing incidence of chronic diseases. The Asia Pacific gene editing market is expected to display fast growth rate in the coming years. The rising geriatric population, modernization of healthcare practices, technological advancements, and government initiatives for controlling diseases are fuelling the growth of the Asia Pacific gene editing market.
South Africa is expected to contribute significantly to the revenue of its regional market. The rising prevalence of sickle cell anemia, HIV, hemophilia and several forms of cancer will drive the industry’s growth.
Major Companies Mentioned in Report
The report mentions and profiles some of the top companies in the global gene editing market, namely Agilent Technologies, AstraZeneca, Cellectis, Editas Medicine, Dharmacon, Qiagen, Sigma-Aldrich, Allele Biotech, Bio Rad, CRISPR Therapeutics, GE Healthcare, Lonza, Recombinetics, and Thermo Fisher Scientific.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report